Knight Therapeutics (KHTRF) announced today that has assumed full commercial activities and is relaunching ONICIT IV in Brazil and Mexico, through its affiliates in those countries. “We are proud to continue providing patients and health care professionals with advanced treatments like ONICIT to help mitigate the debilitating effects of chemotherapy induced nausea and vomiting,” said Samira Sakhia, President and CEO of Knight. “ONICIT is synergistic with our existing oncology portfolio and will continue leveraging the existing commercial and medical footprint.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- KHTRF Upcoming Earnings Report: What to Expect?
- Knight Therapeutics announces launch of Minjuvi in Mexico
- Knight Therapeutics price target raised to C$7.45 from C$6.25 at Stifel
- Knight Therapeutics: Strong Q4 Performance and Strategic Contract Renewal Drive Buy Rating
- Knight Therapeutics’ Earnings Call: Record Revenues Amid Challenges